Biotech trial recruitment has become the deciding factor in whether a study finishes on time or stalls in startup. For sponsors and clinical operations leaders, the question is no longer whether to outsource recruitment but which model actually reaches the patients who need access to trials. Below are seven service models shaping biotech trial recruitment across the US, with a focus on community based access and the embedded research approach that increasingly defines competitive enrollment.
What Is Biotech Trial Recruitment?
Biotech trial recruitment is the set of strategies, technologies, and site partnerships sponsors use to identify, engage, and enroll eligible participants into clinical trials. It spans everything from digital advertising to in clinic identification of candidates already under a physician’s care. The strongest models reduce the time between site activation and first patient enrolled, which is where most biotech trials lose budget and momentum.
How Do Embedded Research Organizations Recruit Patients?
An embedded research organization, or ERO, places clinical trials directly inside existing community medical practices where patients already receive care. This model recruits from a known, trusted patient population rather than relying on cold outreach. Because the research happens where patients already are, enrollment moves faster and retention improves. FOMAT operates the largest ERO network in the United States, with 35 plus investigator sites across six states, giving sponsors direct access to community patient populations that traditional biotech trial recruitment struggles to reach.
1. Embedded Research Site Networks
This model integrates trials into community clinics so recruitment draws from established patient relationships. It is the most effective approach for sponsors who need diverse, real world populations and faster enrollment. Because the patient already trusts the treating physician, consent rates and follow through are typically higher than in standalone recruitment campaigns.
2. Site Networks With Centralized Recruitment
Large multi site networks coordinate recruitment across many locations from a central team. This adds scale, though sponsors should confirm how deeply each site connects to its local patient community, since centralized models can lose the trust advantage that drives community clinic trials.
3. Digital and Direct to Patient Campaigns
These services use online advertising, social media, and prescreening funnels to drive volume. They generate leads quickly but often produce lower quality referrals that burn site staff time on ineligible candidates. They work best as a supplement to site based recruitment rather than a replacement.
4. Patient Registries and Database Matching
Registry models match participants from prebuilt databases of consented individuals. Speed depends entirely on how current and relevant the database is to your therapeutic area, and coverage can thin out in specialized indications.
5. Physician Referral Programs
Referral models rely on community physicians sending eligible patients to nearby trial sites. The approach respects the existing care relationship, though referral leakage and slow handoffs can limit throughput unless the trial sits inside the referring practice itself.
6. Therapeutic Area Specialist Recruiters
Some services focus on a single therapeutic area such as oncology, cardiology, or dermatology, building deep familiarity with the patient profile. Sponsors running narrow indications often value this depth, but it rarely scales across a multi therapeutic portfolio.
7. Hybrid Recruitment Models
Hybrid services combine embedded site access with digital outreach and registry matching. The goal is to capture the speed of digital with the trust of community based recruitment. The success of any hybrid model depends on how strong its underlying site network is, which is why sponsor collaboration with an established ERO often anchors the most reliable programs.
Which Biotech Trial Recruitment Model Works Best?
For most US biotech trials, the embedded research model delivers the strongest combination of speed, diversity, and retention because recruitment happens inside trusted community care settings. Digital and registry tactics add reach, but they perform best layered on top of a real site network rather than standing alone. Sponsors evaluating biotech trial recruitment should weigh how directly each model connects to actual patient populations, since that connection determines enrollment outcomes more than any single tactic. According to the FDA, broad and representative participation strengthens the quality of trial data.
Expand Patient Access to Trials With FOMAT
FOMAT helps biotech sponsors reach diverse community patient populations through the largest embedded research network in the country. To explore how embedded sites can accelerate enrollment for your next study, visit our investigator network or review our approach to diversity in clinical trials.